ClinicalTrials.gg
CompletedNCT00957905Updated Mar 10, 2017Results posted

Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors

A Phase 2 interventional study of Alvocidib Hydrochloride and Fluorouracil in Recurrent Extragonadal Seminoma, Recurrent Malignant Extragonadal Germ Cell Tumor and Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell Tumor, sponsored by National Cancer Institute (NCI). Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-10.

Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 17 studies in Testicular Neoplasms by National Cancer Institute (NCI) — none open to participants now, 1 under way, none of them phase 3. Testicular Neoplasms · National Cancer Institute (NCI).

Started
2009
the only one that year
Phase 2
4 of 17
none open now
Registered
15th of 17
by date

Among the 17 studies in Testicular Neoplasms by National Cancer Institute (NCI), this one is the only one that started in 2009, is one of 4 in phase 2, and was the 15th registered.

Testicular Neoplasms

295 studies on the registry are indexed under Testicular Neoplasms; 51 are open to participants now.

Browse Testicular Neoplasms studies →

Open to participants now

None of the 17 studies in Testicular Neoplasms by National Cancer Institute (NCI) is open now. The open studies under Testicular Neoplasms, anywhere →

Where they have run

Who these studies take

Of the 43 Testicular Neoplasms studies recruiting now, 26 (60%) set no upper age limit and 11 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies in Testicular Neoplasms by National Cancer Institute (NCI) as a file.
02

Study summary

This phase II trial is studying alvocidib and oxaliplatin to see how well they work when given with or without fluorouracil and leucovorin calcium in treating patients with relapsed or refractory germ cell tumors. Drugs used in chemotherapy, such as alvocidib, oxaliplatin, fluorouracil, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving alvocidib together with oxaliplatin with or without fluorouracil and leucovorin calcium may kill more tumor cells.

Read the detailed description

PRIMARY OBJECTIVES:

I. To evaluate the antitumor efficacy of the combination of flavopiridol and oxaliplatin with or without 5-FU and leucovorin in patients with relapsed or refractory GCT. The necessity of 5-FU and leucovorin to the combination will also be indirectly tested in this study.

SECONDARY OBJECTIVES:

I. To further evaluate the safety of flavopiridol in combination with oxaliplatin with or without 5-fluorouracil and leucovorin in patients with refractory or relapsed GCT.

II. To evaluate the time to tumor response (TTR) and progression-free survival for patients with refractory or relapsed GCT treated with flavopiridol in combination with oxaliplatin with or without 5-fluorouracil and leucovorin.

III. To explore the association between treatment response and p21, p53 and apoptotic markers.

OUTLINE: Patients are initially enrolled in part A (closed to accrual as of 11/15/2010). Depending on response to treatment, additional patients may be enrolled in part B.

PART A (alvocidib and oxaliplatin) (closed to accrual as of 11/15/2010): Patients receive alvocidib IV over 1 hour and oxaliplatin IV over 2 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.

PART B (alvocidib and FOLFOX): Patients receive alvocidib IV over 1 hour, oxaliplatin IV over 2 hours, and leucovorin calcium IV over 2 hours followed by fluorouracil IV continuously over 48 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity. Tumor tissue samples may be collected periodically for further laboratory analysis.

After completion of study treatment, patients are followed up every 4-8 weeks.

03

Conditions studied

  • Recurrent Extragonadal Seminoma
  • Recurrent Malignant Extragonadal Germ Cell Tumor
  • Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell Tumor
  • Recurrent Malignant Testicular Germ Cell Tumor
  • Recurrent Ovarian Germ Cell Tumor
  • Stage III Testicular Cancer
  • Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor
  • Stage IV Extragonadal Seminoma
  • Stage IV Ovarian Germ Cell Tumor

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • confirmed germ cell tumor (GCT)

    • Seminoma or non-seminoma
  • Progressive disease after prior cisplatin-based therapy AND meets 1 of the following criteria:

    • Not considered to be a candidate for potentially curative therapy
    • Previously treated with high-dose chemotherapy regimens
    • Does not wish to undergo potentially curative high-dose therapy
  • Measurable or evaluable disease, as defined by 1 of the following criteria:

    • Unidimensionally measurable disease, defined as ≥ 1 malignant tumor mass that can be accurately measured in ≥ 1 dimension as ≥ 20 mm by conventional CT scan or MRI or as ≥ 10 mm by spiral CT scan

      • Bone lesions, ascites, peritoneal carcinomatosis, miliary lesions, pleural or pericardial effusions, lymphangitis of the skin or lung, cystic lesions, or irradiated lesions are not considered
      • Patients with measurable disease only (i.e., normal tumor markers) must have ≥ 1 site of disease that has not been previously irradiated
    • Elevation of alpha-fetoprotein > 15 ng/mL and/or elevation of beta-human chorionic gonadotropin > 2.2 mIU/L

      • If tumor markers are not elevated, ≥ 1 site of measurable disease must be present
  • No known untreated or primary CNS tumor

    • Patients who have undergone local treatment for brain metastases and whose brain metastases are demonstrated to be stable by repeat imaging studies performed ≥ 4 weeks after treatment are eligible
  • performance status 70-100%
  • ≥ 1,000/mm\^3
  • count ≥ 100,000/mm\^3
  • ≥ 8.0 g/dL
  • Serum creatinine ≤ 2.0 times (ULN)
  • Total serum ≤ 1.5 times ULN
  • and ALT ≤ 2.5 times ULN (unless elevation is due to underlying )
  • Not pregnant or nursing
  • Negative pregnancy test by ultrasound
  • Fertile patients must use effective
  • Willing and able to comply with scheduled study visits, treatment plans, laboratory tests, follow-up tests for safety or effectiveness, and other study procedures
  • Mediport or Broviac access required for patients enrolled in part B of the study
  • No serious active infections
  • No significant (≥ grade 2) or persistent ongoing toxicity, including peripheral neuropathy, from prior therapy
  • None of the following within the past 6 months:

    • Myocardial infarction
    • Severe/unstable angina
    • Coronary/peripheral artery bypass graft
    • Symptomatic congestive heart failure
    • Cerebrovascular accident or
    • Pulmonary embolism
  • No to any of the study drugs
  • No other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, interfere with the interpretation of study results, and, in the judgement of the investigator, may make the patient inappropriate for study entry
  • No concurrent anti-retroviral therapy for -positive patients
  • Recovered from prior radiotherapy or surgery

    • Residual grade 1 toxicities allowed
  • No prior alvocidib
  • At least 2 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C), immunotherapy, or radiotherapy
  • More than 4 weeks since prior major surgery
  • No other concurrent approved or anticancer treatment, including surgery, radiotherapy, chemotherapy, biologic-response modifiers, hormone therapy, or immunotherapy
  • No concurrent participation in another investigational treatment clinical trial

    • Concurrent participation in supportive care trials or non-treatment trials (e.g., quality of life or laboratory analysis studies) allowed
  • No concurrent vitamins, antioxidants, herbal preparations, or supplements, except for a single-tablet multivitamin
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Part A (alvocidib and oxaliplatin)

    Patients receive alvocidib IV over 1 hour and oxaliplatin IV over 2 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.

    Drug: Alvocidib Hydrochloride · Drug: Oxaliplatin

  • Experimental
    Part B (alvocidib and FOLFOX)

    Patients receive alvocidib IV over 1 hour, oxaliplatin IV over 2 hours, and leucovorin calcium IV over 2 hours followed by fluorouracil IV continuously over 48 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.

    Drug: Alvocidib Hydrochloride · Drug: Fluorouracil · Drug: Leucovorin Calcium · Drug: Oxaliplatin

Interventions

  • DrugAlvocidibStudies of AlvocidibAlvocidib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: 4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5, 7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidinyl)-, hydrochloride, (-)-cis-, Flavopiridol Hydrochloride, HL-275, HMR 1275, L-86-8275, L-868275, MDL 107,826A, MDL-107826A

  • Given IV

    Also known as: 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Actino-Hermal, Adrucil, Arumel, Cytosafe, Efudex, Efurix, Fiverocil, Fluoro Uracil, Fluoroplex, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Flurox, Ribofluor, Ro 2-9757, Ro-2-9757, Timazin

  • DrugLeucovorinStudies of LeucovorinLeucovorin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin

  • Given IV

    Also known as: 1-OHP, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    Number of Participants with Partial Response (PR), Stable Disease (SD), Progression of Disease (POD) Per Response Evaluation Criteria In Solid Tumors Criteria" (RECIST v1.0) for target lesions and assessed by MRI and/or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for a Partial Response nor sufficient increase to qualify for Progression of Disease (POD); POD, 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

    Time frame: Within 3 courses of treatment

Other outcomes

  1. Toxicity

    graded using the NCI CTCAE version 4.0.See adverse event section

    Time frame: Up to 4 years

  2. Progression-free Survival

    Time frame: From treatment start until first documented progression or death, assessed up to 4 years

  3. Time to Tumor Response

    Time frame: From treatment start until first documented CR or PR, assessed up to 4 years

07

Results

Posted Mar 10, 2017

Participant flow

Part A
Participant flow — Part A
MilestonePart APart B
Started70
Completed70
Not completed00
Part B
Participant flow — Part B
MilestonePart APart B
Started029
Completed025
Not completed04
Withdrew: Not treated01
Withdrew: Physician decision01
Withdrew: Death01
Withdrew: Protocol violation01

Outcome measures

PrimaryObjective Response Rate

Number of Participants with Partial Response (PR), Stable Disease (SD), Progression of Disease (POD) Per Response Evaluation Criteria In Solid Tumors Criteria" (RECIST v1.0) for target lesions and assessed by MRI and/or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for a Partial Response nor sufficient increase to qualify for Progression of Disease (POD); POD, 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

Time frame:
Within 3 courses of treatment
Reported as:
Number · participants
Objective Response Rate
participantsPart A (Alvocidib and Oxaliplatin)Part B (Alvocidib and FOLFOX)
Partial Response06
Stable Disease210
Progression of Disease59
Other pre-specifiedToxicity

graded using the NCI CTCAE version 4.0.See adverse event section

Time frame:
Up to 4 years

Results for this outcome have not been posted.

Other pre-specifiedProgression-free Survival
Time frame:
From treatment start until first documented progression or death, assessed up to 4 years

Results for this outcome have not been posted.

Other pre-specifiedTime to Tumor Response
Time frame:
From treatment start until first documented CR or PR, assessed up to 4 years

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A (Alvocidib and Oxaliplatin)—4/7 (57.1%)5/7 (71.4%)
Part B (Alvocidib and FOLFOX)—7/29 (24.1%)23/29 (79.3%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventPart A (Alvocidib and Oxaliplatin)Part B (Alvocidib and FOLFOX)
Neoplasms ben/mal/unk (inc cyst/polyp) Other, specNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/70/29
FeverGeneral disorders1/70/29
Intracranial hemorrhageNervous system disorders1/70/29
HypophosphatemiaMetabolism and nutrition disorders1/70/29
Infective myositisInfections and infestations1/70/29
NauseaGastrointestinal disorders1/70/29
HeadacheNervous system disorders1/70/29
Platelet count decreaseInvestigations1/70/29
HypokalemiaMetabolism and nutrition disorders1/70/29
VomitingGastrointestinal disorders1/70/29
Most frequent other events
Showing 10 of 22
Most frequent other events
EventPart A (Alvocidib and Oxaliplatin)Part B (Alvocidib and FOLFOX)
Platelet count decreasedInvestigations2/717/29
Neutrophil count decreasedInvestigations1/712/29
White blood cell decreasedInvestigations2/712/29
Lymphocyte count decreasedInvestigations2/710/29
Alkaline phosphatase increasedInvestigations2/72/29
AnemiaBlood and lymphatic system disorders2/78/29
NauseaGastrointestinal disorders0/78/29
VomitingGastrointestinal disorders0/77/29
HypocalcemiaMetabolism and nutrition disorders1/76/29
HypophosphatemiaMetabolism and nutrition disorders1/76/29

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Part A (Alvocidib and Oxaliplatin)Part B (Alvocidib and FOLFOX)Total
<=18 years000
Between 18 and 65 years72936
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Part A (Alvocidib and Oxaliplatin)Part B (Alvocidib and FOLFOX)Total
Female011
Male72835
Region of Enrollment
Region of Enrollment(participants)Part A (Alvocidib and Oxaliplatin)Part B (Alvocidib and FOLFOX)Total
United States72936
08

Study locations

10 sites
  • Tower Cancer Research Foundation
    Beverly Hills, California 90211-1850, United States
  • City of Hope Comprehensive Cancer Center
    Duarte, California 91010, United States
  • USC / Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • University of California Davis Comprehensive Cancer Center
    Sacramento, California 95817, United States
  • University of Chicago Comprehensive Cancer Center
    Chicago, Illinois 60637, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • UPMC-Presbyterian Hospital
    Pittsburgh, Pennsylvania 15213, United States
  • University of Pittsburgh Cancer Institute (UPCI)
    Pittsburgh, Pennsylvania 15232, United States
  • Riverview Hospital
    Wisconsin Rapids, Wisconsin 54494, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2009
First posted
Aug 13, 2009
Start
Jun 2009
Primary completionActual
Aug 2014
CompletionActual
Aug 2014
Results first posted
Mar 10, 2017
Last update
Mar 10, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00957905
Responsible party
Sponsor
First posted
Aug 13, 2009
Start date
Jun 2009
Primary completion
Aug 2014
Completion
Aug 2014
Results posted
Mar 10, 2017
Last update
Mar 10, 2017

Study contacts

Darren Feldman
principal investigator · Memorial Sloan Kettering Cancer Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alvocidib · Oxaliplatin

Start the discussion